Efficacy, Tolerability, and Safety Study of DFN-15

PHASE3CompletedINTERVENTIONAL
Enrollment

622

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

May 31, 2019

Conditions
Migraine Headache
Interventions
DRUG

DFN-15 Active

OTHER

DFN-15 Placebo

Trial Locations (45)

10018

Site 705, Manhattan

14221

Site 743, Williamsville

14226

Site 746, Amherst

19063

Site 717, Media

19107

Site 731, Philadelphia

21236

Site 712, Baltimore

23454

Site 714, Virginia Beach

27612

Site 715, Raleigh

29621

Site 710, Anderson

30030

Site 720, Decatur

30513

Site 740, Blue Ridge

32256

Site 721, Jacksonville

32720

Site 735, DeLand

33016

Site 711, Hialeah

35216

Site 744, Birmingham

37421

Site 724, Chattanooga

45255

Site 728, Cincinnati

45424

Site 707, Dayton

50265

Site 734, West Des Moines

55402

Site 704, Minneapolis

63042

Site 736, Hazelwood

65807

Site 737, Springfield

66208

Site 739, Prairie Village

67205

Site 713, Wichita

71105

Site 706, Shreveport

72211

Site 723, Little Rock

72758

Site 718, Rogers

73103

Site 701, Oklahoma City

75024

Site 702, Plano

78731

Site 719, Austin

80907

Site 726, Colorado Springs

85018

Site 727, Phoenix

89103

Site 745, Las Vegas

90017

Site 709, Los Angeles

90404

Site 725, Santa Monica

91786

Site 733, Upland

92103

Site 729, San Diego

92868

Site 708, Orange

93065

Site 738, Simi Valley

97301

Site 741, Salem

98007

Site 722, Bellevue

02131

Site 703, Boston

02740

Site 730, New Bedford

08009

Site 716, Berlin

02865

Site 742, Lincoln

All Listed Sponsors
lead

BioDelivery Sciences International

INDUSTRY

NCT03006276 - Efficacy, Tolerability, and Safety Study of DFN-15 | Biotech Hunter | Biotech Hunter